Enzymotec has announced that it’s patent application "Glycerophospholipids containing omega-3 and omega-6 fatty acid” (Pat. No. 2004282006) is now officially granted in Australia.
The patent covers methods for improving cognitive and behavioral parameters by administration of phosphatidylserine (PS) containing the omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA).
Sharp PS®GOLD has a unique composition, which mimics brain PS. Recent clinical studies have demonstrated its capacity to significantly increase DHA level in the brain and subsequently improve cognitive performance due to the combined action of PS and DHA. Recently the Sharp-PS® -brand line was extended by the addition of Krill-PS into Enzymotec's product portfolio."The Australian market is an important market that holds a big potential for Enzymotec's products due to its dynamic nature and proximity to South East Asia" says Mr. Gil Kirtovsky the Business Unit Manager.
"As part of our strategy, we continue to invest efforts in order to strengthen our IP position all over the world" says Director of R&D. "There are numerous pending patents covering process, efficacy, health benefits and composition of our products around the world," concludes Gil.
Enzymotec is a dynamic biotech company and a leading global developer, producer and supplier of lipid-based products and solutions. Enzymotec develops, manufactures and markets innovative bio-active ingredients and finished products based on sophisticated proprietary technologies. Enzymotec's products support general health, from cardiovascular to cognitive functions, in the largest therapeutic markets and deliver innovative solutions in three business segments:
1) Orthomolecular Medicine - Practice of preventing and treating diseases by providing the body with optimal amounts of substances that are natural to the body
2) Infant Nutrition -Providing lipid compositions that mimic the fat in human milk for the wellbeing of infants
3) BioActive Ingredients – Providing ingredients for the pharma, dietary supplements and functional foods markets.